Dynacure’s Antisense Approach To Rare Myopathies Gets Funding Boost

Ionis Collaborating On Development

France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.    

Skeletal_Muscle
Skeletal Muscle • Source: Shutterstock

Just four years after inception, the France/US rare diseases start-up Dynacure SAS has raised €50m ($55m) in a series C funding to help support an ongoing Phase I/II trial of its lead antisense candidate, DYN101, in patients with myotubular and centronuclear myopathies (CNMs).

As well as the ongoing trial in adults, the proceeds from the fundraising will also be used to expand the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.